NCT03188900

Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia

New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 236 (actual)
• Sponsor: Assistance Publique - Hôpitaux de Paris · Academic / Other
• Sex: Female
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The aim of the study is to setup a collection of maternal plasma and serum from patients with preeclampsia and normal pregnancy for in vitro validation of new therapeutics based on extra-corporal removal of sFlt-1

Detailed description

A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP) : * Between 20WG and 23WG+6D : 20 patients with PE and 30 patients with NP * Between 24WG and 27WG+6D : 20 patients with PE and 30 patients with NP * Between 28WG and 31WG+6D : 20 patients with PE and 30 patients with NP * Between 32WG and 35WG+6D : 20 patients with PE and 30 patients with NP * Between 36WG and 40WG+6D : 20 patients with PE and 30 patients with NP

Conditions

• Preeclampsia

Interventions

Type	Name	Description
BIOLOGICAL	A collection of maternal plasma and serum	A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)

Timeline

• Start date: 2017-06-12
• Primary completion: 2019-06-12
• Completion: 2019-06-12
• First posted: 2017-06-16
• Last updated: 2026-03-27

Locations

1 site across 1 country: France